Abstract
HomeStrokeVol. 39, No. 4Response to Letter by Silva et al Free AccessLetterPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessLetterPDF/EPUBResponse to Letter by Silva et al Joseph P. Broderick E. S. Connolly Carlos S. Kase Paul Vespa Derk W. Krieger Daniel F. Hanley Marc Mayberg Edward Feldmann Lewis B. Morgenstern Mario Zuccarello Christopher S. Ogilvy Joseph P. BroderickJoseph P. Broderick Division of Neurology, University of Cincinnati, Cincinnati, Ohio Search for more papers by this author E. S. ConnollyE. S. Connolly Columbia University Search for more papers by this author Carlos S. KaseCarlos S. Kase Boston University Medical Center, Boston, Mass Search for more papers by this author Paul VespaPaul Vespa University of California, Los Angeles, Los Angeles, Calif Search for more papers by this author Derk W. KriegerDerk W. Krieger The Cleveland Clinic Foundation, Cleveland, Ohio Search for more papers by this author Daniel F. HanleyDaniel F. Hanley Johns Hopkins University, Baltimore, Md Search for more papers by this author Marc MaybergMarc Mayberg Seattle Neuroscience Institute Search for more papers by this author Edward FeldmannEdward Feldmann Brown Medical School Search for more papers by this author Lewis B. MorgensternLewis B. Morgenstern The University of Michigan Health System Search for more papers by this author Mario ZuccarelloMario Zuccarello University of Cincinnati, Cincinnati, Ohio Search for more papers by this author Christopher S. OgilvyChristopher S. Ogilvy Massachusetts General Hospital, Harvard Medical School, Boston, Mass Search for more papers by this author Originally published28 Feb 2008https://doi.org/10.1161/STROKEAHA.107.502781Stroke. 2008;39:e68Other version(s) of this articleYou are viewing the most recent version of this article. Previous versions: February 28, 2008: Previous Version 1 Response:We appreciate the comments of Dr Silva and colleagues clarifying that etomidate should be used as rapid induction for intubation rather than as a long-term sedative. We also concur that remifentanil is a useful medication for pain control/sedation. The published ASA Guidelines on Management of Spontaneous Intracerebral Hemorrhage were not meant to give a comprehensive review on each and every agent and its proper use in various settings but rather to briefly mention medications that are used for sedation and pain control in patients with intracerebral hemorrhage who require intubation and ventilation. There are excellent reviews elsewhere that describe detailed approaches to sedation and pain control in the neurocritical care setting. As far as we are aware, no specific randomized trials have been conducted that assess the benefits of one particular sedative or analgesic over another in patients with intracranial hemorrhages. This is a potential area of future research.DisclosuresNone. Previous Back to top Next FiguresReferencesRelatedDetails April 2008Vol 39, Issue 4 Advertisement Article InformationMetrics https://doi.org/10.1161/STROKEAHA.107.502781 Originally publishedFebruary 28, 2008 PDF download Advertisement
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
